## Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger

Vaccines and Other Immunizing Agents in the Child and Adolescent Immunization Schedule*

| Monoclonal antibody                                                                            | Abbreviation(s)                                                                                | Trade name(s)                                                                                  |
|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Respiratory syncytial virus monoclonal antibody (Nirsevimab)                                   | RSV-mAb                                                                                        | Beyfortus                                                                                      |
| Vaccine                                                                                        | Abbreviation(s)                                                                                | Trade name(s)                                                                                  |
| COVID-19 vaccine                                                                               | 1vCOV-mRNA                                                                                     | Comirnaty, mNexspike, Spikevax                                                                 |
|                                                                                                | 1vCOV-aPS                                                                                      | Nuvaxovid                                                                                      |
| Dengue vaccine                                                                                 | DEN4CYD                                                                                        | Dengvaxia                                                                                      |
| Diphtheria, tetanus, and acellular pertussis vaccine                                           | DTaP                                                                                           | Daptacel Infanrix                                                                              |
| Haemophilusinfluenzae type bvaccine                                                            | Hib (PRP-T) Hib (PRP-OMP)                                                                      | ActHIB Hiberix PedvaxHIB                                                                       |
| Hepatitis Avaccine                                                                             | HepA                                                                                           | Havrix Vaqta                                                                                   |
| Hepatitis B vaccine                                                                            | HepB                                                                                           | Engerix-B RecombivaxHB                                                                         |
| Humanpapillomavirus vaccine                                                                    | HPV                                                                                            | Gardasil 9                                                                                     |
| Influenza vaccine (inactivated: egg-based)                                                     | IIV3                                                                                           | Multiple                                                                                       |
| Influenza vaccine (inactivated: cell-culture)                                                  | ccIIV3                                                                                         | Flucelvax                                                                                      |
| Influenza vaccine (live, attenuated)                                                           | LAIV3                                                                                          | FluMist                                                                                        |
| Measles, mumps, and rubella vaccine                                                            | MMR                                                                                            | M-M-R II Priorix                                                                               |
| Meningococcal serogroups A, C,W,Yvaccine                                                       | MenACWY-CRM MenACWY-TT                                                                         | Menveo MenQuadfi                                                                               |
| Meningococcal serogroup B vaccine                                                              | MenB-4C MenB-FHbp                                                                              | Bexsero Trumenba                                                                               |
| Meningococcal serogroup A, B, C,W,Yvaccine                                                     | MenACWY-TT/ MenB-FHbp                                                                          | Penbraya                                                                                       |
| Monkeypox vaccine                                                                              | Mpox                                                                                           | Jynneos                                                                                        |
| Pneumococcal conjugate vaccine                                                                 | PCV15 PCV20                                                                                    | Vaxneuvance Prevnar 20                                                                         |
| Pneumococcal polysaccharide vaccine                                                            | PPSV23                                                                                         | Pneumovax 23                                                                                   |
| Poliovirus vaccine (inactivated)                                                               | IPV                                                                                            | Ipol                                                                                           |
| Respiratory syncytial virus vaccine                                                            | RSV                                                                                            | Abrysvo                                                                                        |
| Rotavirus vaccine                                                                              | RV1 RV5                                                                                        | Rotarix RotaTeq                                                                                |
| Tetanus, diphtheria, and acellular pertussis vaccine                                           | Tdap                                                                                           | Adacel Boostrix                                                                                |
| Tetanus and diphtheria vaccine                                                                 | Td                                                                                             | Tenivac Tdvax                                                                                  |
| Varicella vaccine                                                                              | VAR                                                                                            | Varivax                                                                                        |
| Combination vaccines (use combination vaccines instead of separate injections whenappropriate) | Combination vaccines (use combination vaccines instead of separate injections whenappropriate) | Combination vaccines (use combination vaccines instead of separate injections whenappropriate) |
| DTaP, hepatitis B, and inactivated poliovirus vaccine                                          | DTaP-HepB-IPV                                                                                  | Pediarix                                                                                       |
| DTaP, inactivated poliovirus, and Haemophilusinfluenzae type bvaccine                          | DTaP-IPV/Hib                                                                                   | Pentacel                                                                                       |
| DTaP and inactivated poliovirus vaccine                                                        | DTaP-IPV                                                                                       | Kinrix Quadracel                                                                               |
| DTaP, inactivated poliovirus, Haemophilusinfluenzae type b, and hepatitis B vaccine            | DTaP-IPV-Hib- HepB                                                                             | Vaxelis                                                                                        |
| Measles, mumps, rubella, and varicella vaccine                                                 | MMRV                                                                                           | ProQuad                                                                                        |

<!-- image -->

2025

## How to use the child and adolescent immunization schedule

1

Determine recommended vaccine by age (Table 1)

## Report

- y Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- y Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or 800-822-7967

## Questions or comments

Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.-8 p.m. ET, Monday through Friday, excluding holidays.

<!-- image -->

Download the CDC Vaccine Schedules app for providers at www.cdc.gov/vaccines/hcp/imz-schedules/app.html

## Helpful information

- y Complete Advisory Committee on Immunization Practices (ACIP) recommendations: www.cdc.gov/acip-recs/hcp/vaccine-specific/index.html
- y ACIP Shared Clinical Decision-Making Recommendations: www.cdc.gov/acip/vaccine-recommendations/shared-clinical-decision-making.html
- y General Best Practice Guidelines for Immunization (including contraindications and precautions): www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- y Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html
- y Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): www.cdc.gov/surv-manual/php/

<!-- image -->

2

Determine recommended interval for catchup vaccination (Table 2)

3

Assess need for additional recommended vaccines by medical condition or other indication (Table 3)

<!-- image -->

Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)

5

Review contraindications and precautions for vaccine types (Appendix)

<!-- image -->

6

Review new or updated ACIP guidance (Addendum)

Scan QR code for access to online schedule

<!-- image -->

<!-- image -->

## Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2025

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2).

populations

<!-- image -->

<!-- image -->

## Table 2 Recommended Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More than 1 Month Behind, United States, 2025

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age. Always use this table in conjunction with Table 1 and the Notes that follow.

|                                                                   | Childrenage4monthsthrough6years                       | Childrenage4monthsthrough6years                                                                                                                                                                                                                                       | Childrenage4monthsthrough6years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Childrenage4monthsthrough6years                                                                                                                                                  | Childrenage4monthsthrough6years                                                                                                     |
|-------------------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| Vaccine                                                           | MinimumAgefor                                         | MinimumIntervalBetweenDoses                                                                                                                                                                                                                                           | MinimumIntervalBetweenDoses                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | MinimumIntervalBetweenDoses                                                                                                                                                      | MinimumIntervalBetweenDoses                                                                                                         |
|                                                                   | Dose1                                                 | Dose1toDose2                                                                                                                                                                                                                                                          | Dose2toDose3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Dose3toDose4                                                                                                                                                                     | Dose4toDose5                                                                                                                        |
| Hepatitis B                                                       | Birth                                                 | 4weeks                                                                                                                                                                                                                                                                | 8weeks and at least 16weeksafter firstdose minimumagefor the final dose is 24 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                  |                                                                                                                                     |
| Rotavirus                                                         | 6 weeks Maximumagefor first dose is 14 weeks, 6 days. | 4weeks                                                                                                                                                                                                                                                                | 4weeks maximumagefor final dose is 8 months, 0 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                  |                                                                                                                                     |
| Diphtheria, tetanus, and acellular pertussis                      | 6 weeks                                               | 4weeks                                                                                                                                                                                                                                                                | 4weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 6months                                                                                                                                                                          | 6months Afifth dose is not necessary if the fourth dose was administered at age 4 years or older and at least 6 months after dose 3 |
| Haemophilusinfluenzae typeb                                       | 6 weeks                                               | Nofurtherdosesneeded if first dose was administered at age 15 months or older. 4weeks if first dose was administered before the 1st birthday. 8weeks(asfinal dose) if first dose was administered at age 12 through 14 months.                                        | Nofurtherdosesneeded if previous dose was administered at age 15 months or older 4weeks if current age is younger than 12 months and first dose was administered at younger than age 7 months and at least 1 previous dose was PRP-T (ActHib, Pentacel, Hiberix), Vaxelis orunknown 8weeks and age12-59months(asfinal dose) if current age is younger than 12 months and first dose was administered at age 7-11 months; OR if current age is 12-59 months and first dose was administered before the 1st birthday and second dose was administered at younger than 15 months; OR if both doses were PedvaxHIB and were administered before the 1st birthday | 8weeks(asfinal dose) This dose only necessary for childrenage12-59monthswho received 3 doses before the 1st birthday.                                                            |                                                                                                                                     |
| Pneumococcal conjugate                                            | 6 weeks                                               | Nofurtherdosesneeded for healthy children if first dose was administered at age 24 months or older 4weeks if first dose was administered before the 1st birthday 8weeks(asfinal dosefor healthy children) if first dose was administered at the 1st birthday or after | Nofurtherdosesneeded for healthy children if previous dose was administered at age 24 months or older 4weeks if current age is younger than 12 months and previous dose was administered at <7 months old 8weeks(asfinal dosefor healthy children) if previous dose was administered between 7-11 months (wait until at least 12 months old); OR if current age is 12 months or older and at least 1 dose was administered before age 12 months                                                                                                                                                                                                              | 8weeks(asfinal dose) This dose is only necessary for children age 12- 59 months regardless of risk, or age 60-71 months with any risk, whoreceived 3 doses before age 12 months. |                                                                                                                                     |
| Inactivated poliovirus                                            | 6 weeks                                               | 4weeks                                                                                                                                                                                                                                                                | 4weeks if current age is <4 years 6months(asfinal dose) if current age is 4 years or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 6months(minimumage4years for final dose)                                                                                                                                         |                                                                                                                                     |
| Measles, mumps, rubella                                           | 12 months                                             | 4weeks                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                  |                                                                                                                                     |
| Varicella                                                         | 12 months                                             | 3months                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                  |                                                                                                                                     |
| HepatitisA                                                        | 12 months                                             | 6months                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                  |                                                                                                                                     |
| MeningococcalACWY                                                 | 2monthsMenACWY-CRM                                    | 8weeks                                                                                                                                                                                                                                                                | See Notes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | See Notes                                                                                                                                                                        |                                                                                                                                     |
| Childrenandadolescentsage7-18years                                | Childrenandadolescentsage7-18years                    | Childrenandadolescentsage7-18years                                                                                                                                                                                                                                    | Childrenandadolescentsage7-18years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Childrenandadolescentsage7-18years                                                                                                                                               | Childrenandadolescentsage7-18years                                                                                                  |
| MeningococcalACWY                                                 | Not applicable (N/A)                                  | 8weeks                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                  |                                                                                                                                     |
| Tetanus, diphtheria; tetanus, diphtheria, and acellular pertussis | 7 years                                               | 4weeks                                                                                                                                                                                                                                                                | 4weeks if first dose of DTaP/DT was administered before the 1st birthday 6months(asfinal dose) if first dose of DTaP/DT orTdap/Td was administered at or after the 1st birthday                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 6months if first dose of DTaP/DT was administered before the 1st birthday                                                                                                        |                                                                                                                                     |
| Humanpapillomavirus                                               | 9 years                                               | Routine dosing intervals are recommended.                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                  |                                                                                                                                     |
| HepatitisA                                                        | N/A                                                   | 6months                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                  |                                                                                                                                     |
| Hepatitis B                                                       | N/A                                                   | 4weeks                                                                                                                                                                                                                                                                | 8weeks and at least 16weeksafter firstdose                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                  |                                                                                                                                     |
| Inactivated poliovirus                                            | N/A                                                   | 4weeks                                                                                                                                                                                                                                                                | 6months Afourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Afourth dose of IPV is indicated if all previous doses were administered at <4 years OR if the third dose was administered <6 months after the second dose.                      |                                                                                                                                     |
| Measles, mumps, rubella                                           | N/A                                                   | 4weeks                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                  |                                                                                                                                     |
| Varicella                                                         | N/A                                                   | 3months if younger than age 13 years. 4weeks if age 13 years or older                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                  |                                                                                                                                     |
| Dengue                                                            | 9 years                                               | 6months                                                                                                                                                                                                                                                               | 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                  |                                                                                                                                     |

<!-- image -->

## Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2025

Always use this table in conjunction with Table 1 and the Notes that follow. Medical conditions are often not mutually exclusive. If multiple conditions are present, refer to guidance in all relevant columns. See Notes for medical conditions not listed.

<!-- image -->

| Vaccine andother immunizing                                                                            | Pregnancy                                                                                              | Immunocompromised (excludingHIV                                                                                                   | HIVinfectionCD4 percentageandcount a CSFleak               | HIVinfectionCD4 percentageandcount a CSFleak                    | agents                                                          | Asplenia or persistent complement component deficiencies        | Heart disease or chronic lung disease                                                        | Kidney failure, End-stage renal disease or ondialysis          |                       |                       | Diabetes                 |
|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------|-----------------------|-----------------------|--------------------------|
| Vaccine andother immunizing                                                                            | Pregnancy                                                                                              | infection)                                                                                                                        | <15%or <200/mm 3                                           | ≥15%and ≥200/mm 3                                               | agents                                                          | Asplenia or persistent complement component deficiencies        | Heart disease or chronic lung disease                                                        | Chronic disease                                                |                       |                       | Diabetes                 |
| RSV-mAb (nirsevimab)                                                                                   |                                                                                                        | 2nd RSV season                                                                                                                    |                                                            | 1 dose depending on maternal RSV vaccination status (See Notes) | 1 dose depending on maternal RSV vaccination status (See Notes) | 1 dose depending on maternal RSV vaccination status (See Notes) | 2nd RSV season for chronic lung disease (See Notes)                                          | 1 dose RSV vaccination                                         | depending on maternal | depending on maternal | Notes)                   |
| HepatitisB                                                                                             |                                                                                                        |                                                                                                                                   |                                                            |                                                                 |                                                                 |                                                                 |                                                                                              |                                                                |                       |                       |                          |
| Rotavirus                                                                                              |                                                                                                        | SCID b                                                                                                                            |                                                            |                                                                 |                                                                 |                                                                 |                                                                                              |                                                                |                       |                       |                          |
|                                                                                                        | DTaP                                                                                                   |                                                                                                                                   |                                                            |                                                                 |                                                                 |                                                                 |                                                                                              |                                                                |                       |                       |                          |
| DTaP/Tdap                                                                                              | Tdap: 1 dose each pregnancy                                                                            |                                                                                                                                   |                                                            |                                                                 |                                                                 |                                                                 |                                                                                              |                                                                |                       |                       |                          |
| Hib                                                                                                    |                                                                                                        | HSCT: 3 doses                                                                                                                     | See                                                        | Notes                                                           |                                                                 | See Notes                                                       |                                                                                              |                                                                |                       |                       |                          |
| Pneumococcal                                                                                           |                                                                                                        |                                                                                                                                   |                                                            |                                                                 |                                                                 |                                                                 |                                                                                              |                                                                |                       |                       |                          |
| IPV                                                                                                    |                                                                                                        |                                                                                                                                   |                                                            |                                                                 |                                                                 |                                                                 |                                                                                              |                                                                |                       |                       |                          |
|                                                                                                        | See Notes                                                                                              | Additional doses maybenecessary (See Notes)                                                                                       |                                                            |                                                                 |                                                                 |                                                                 | See Notes                                                                                    |                                                                |                       | COVID-19              |                          |
| Influenza inactivated                                                                                  |                                                                                                        | Solid organ transplant: 18yrs (See Notes)                                                                                         |                                                            |                                                                 |                                                                 |                                                                 |                                                                                              |                                                                |                       |                       |                          |
| LAIV3                                                                                                  |                                                                                                        |                                                                                                                                   |                                                            |                                                                 |                                                                 |                                                                 | Asthma, wheezing: 2-4 years c                                                                |                                                                |                       |                       |                          |
| MMR                                                                                                    | *                                                                                                      |                                                                                                                                   |                                                            |                                                                 |                                                                 |                                                                 |                                                                                              |                                                                |                       |                       |                          |
| VAR                                                                                                    | *                                                                                                      |                                                                                                                                   |                                                            |                                                                 |                                                                 |                                                                 |                                                                                              |                                                                |                       |                       |                          |
| HepatitisA                                                                                             |                                                                                                        |                                                                                                                                   |                                                            |                                                                 |                                                                 |                                                                 |                                                                                              |                                                                |                       |                       |                          |
| HPV                                                                                                    | *                                                                                                      | 3-dose series (See                                                                                                                | Notes)                                                     |                                                                 |                                                                 |                                                                 |                                                                                              |                                                                |                       |                       |                          |
| MenACWY                                                                                                |                                                                                                        |                                                                                                                                   |                                                            |                                                                 |                                                                 |                                                                 |                                                                                              |                                                                |                       |                       |                          |
| MenB                                                                                                   |                                                                                                        |                                                                                                                                   |                                                            |                                                                 |                                                                 |                                                                 |                                                                                              |                                                                |                       |                       |                          |
| RSV(Abrysvo)                                                                                           | Seasonal administration (See Notes)                                                                    |                                                                                                                                   |                                                            |                                                                 |                                                                 |                                                                 |                                                                                              |                                                                |                       |                       |                          |
| Dengue                                                                                                 |                                                                                                        |                                                                                                                                   |                                                            |                                                                 |                                                                 |                                                                 |                                                                                              |                                                                |                       |                       |                          |
| Mpox                                                                                                   | See Notes                                                                                              |                                                                                                                                   |                                                            |                                                                 |                                                                 |                                                                 |                                                                                              |                                                                |                       |                       |                          |
|  Recommended for all age- eligible children who lack documentation of a complete vaccination series  |  Recommended for all age- eligible children who lack documentation of a complete vaccination series  | Not recommended for all children, but recommended for some children based on increased risk for or severe outcomes from disease  | Vaccination is based on shared clinical decision- making  | Vaccination is based on shared clinical decision- making       | Additional doses may be necessary based on medical condition or | indications. See Notes.                                         |  Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction |  Contraindicated or recommended *Vaccinate after if indicated | not pregnancy,  No   | not pregnancy,  No   | Guidance/ Not Applicable |

<!-- image -->

For vaccination recommendations for persons ages 19 years or older, see the Recommended Adult Immunization Schedule, 2025.

## Additional information

- y For calculating intervals between doses, 4 weeks = 28 days. Intervals of ≥4 months are determined by calendar months.
- y Within a number range (e.g., 12-18), a dash (-) should be read as 'through.'
- y Vaccine doses administered ≤4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum age or minimum interval should not be counted as valid and should be repeated as age appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see Table 3-2, Recommended and minimum ages and intervals between vaccine doses, in General Best Practice Guidelines for Immunization at www.cdc.gov/vaccines/hcp/ imz-best-practices/timing-spacing-immunobiologics.html.
- y Information on travel vaccination requirements and recommendations is available at www.cdc.gov/travel/.
- y For vaccination of persons with immunodeficiencies, see Table 8-1, Vaccination of persons with primary and secondary immunodeficiencies, in General Best Practice Guidelines for Immunization at www.cdc.gov/vaccines/hcp/acip-recs/ general-recs/immunocompetence.html, and Immunization in Special Clinical Circumstances (In: Kimberlin DW, Barnett ED, Lynfield Ruth, Sawyer MH, eds. Red Book: 2021-2024 Report of the Committee on Infectious Diseases . 32nd ed. Itasca, IL: American Academy of Pediatrics; 2021:72-86).
- y For information about vaccination in the setting of a vaccinepreventable disease outbreak, contact your state or local health department.
- y The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All vaccines included in the child and adolescent vaccine schedule are covered by VICP except dengue, PPSV23, RSV, Mpox and COVID-19 vaccines. Mpox and COVID-19 vaccines are covered by the Countermeasures Injury Compensation Program (CICP). For more information, see www.hrsa.gov/vaccinecompensation or www.hrsa.gov/cicp.

## COVID-19 vaccination

(minimum age: 6 months [Spikevax], 5 years [Comirnaty], 12 years [mNexspike, Novaxovid])

## Shared clinical decision-making

Vaccination based on individual-based decision-making -with an emphasis that the risk-benefit of vaccination is most favorable for individuals who are at an increased risk for severe COVID-19 disease and lowest for individuals who are not at an increased risk according to the CDC list of COVID-19 risk factors (see www. cdc.gov/covid/hcp/clinical-care/underlying-conditions.html). For additional information on shared clinical decision-making, see www.cdc.gov/acip/vaccine-recommendations/sharedclinical-decision-making.html

Current COVID-19 schedule and dosage formulation available at www.cdc.gov/covidschedule.

Administer an age-appropriate COVID-19 vaccine product for each dose. There is no preferential recommendation for the use of one COVID-19 vaccine over another when more than one recommended age-appropriate vaccine is available.

WHITE SPACE INTENTIONALLY LEFT BLANK

<!-- image -->

## Dengue vaccination

(minimum age: 9 years)

## Routine vaccination

- y Age 9-16 years living in areas with endemic dengue AND have laboratory confirmation of previous dengue infection
- 3-dose series administered at 0, 6, and 12 months
- y Endemic areas include Puerto Rico, American Samoa, US Virgin Islands, Federated States of Micronesia, Republic of Marshall Islands, and the Republic of Palau. For updated guidance on dengue endemic areas and pre-vaccination laboratory testing see www.cdc.gov/mmwr/volumes/70/rr/ rr7006a1.htm?s\_cid=rr7006a1\_w and www.cdc.gov/dengue/ index.html
- y Dengue vaccine should not be administered to children traveling to or visiting endemic dengue areas.

Diphtheria, tetanus, and pertussis (DTaP) vaccination (minimum age: 6 weeks [4 years for Kinrix or Quadracel])

## Routine vaccination

- y 5-dose series (3-dose primary series at age 2, 4, and 6 months, followed by booster doses at ages 15-18 months and 4-6 years)
- -Prospectively: Dose 4 may be administered as early as age 12 months if at least 6 months have elapsed since dose 3.
- -Retrospectively: A 4th dose that was inadvertently administered as early as age 12 months may be counted if at least 4 months have elapsed since dose 3.

## Catch-up vaccination

- y Dose 5 is not necessary if dose 4 was administered at age 4 years or older and at least 6 months after dose 3.
- y For other catch-up guidance, see Table 2.

## Special situations

- y Children younger than age 7 years with a contraindication specific to the pertussis component of DTaP: May administer Td for all recommended remaining doses in place of DTaP. Encephalopathy within 7 days of vaccination when not attributable to another identifiable cause is the only contraindication specific to the pertussis component of DTaP . For additional information, see www.cdc.gov/pertussis/hcp/ vaccine-recommendations/td-offlabel.html.
- y Wound management in children younger than age 7 years with history of 3 or more doses of tetanus-toxoidcontaining vaccine: For all wounds except clean and minor wounds, administer DTaP if more than 5 years since last dose of tetanus-toxoid-containing vaccine. For detailed information, see www.cdc.gov/mmwr/volumes/67/rr/ rr6702a1.htm.

<!-- image -->

## Haemophilus influenzae type b vaccination (minimum age: 6 weeks)

## Routine vaccination

- y ActHIB, Hiberix, Pentacel, or Vaxelis: 4-dose series (3-dose primary series at age 2, 4, and 6 months, followed by a booster dose* at age 12-15 months)
- *Vaxelis is not recommended for use as a booster dose. A different Hib-containing vaccine should be used for the booster dose.
- y PedvaxHIB: 3-dose series (2-dose primary series at age 2 and 4 months, followed by a booster dose at age 12-15 months)
- y American Indian and Alaska Native infants: Vaxelis and PedvaxHIB preferred over other Hib vaccines for the primary series.

## Catch-up vaccination

- y Dose 1 at age 7-11 months: Administer dose 2 at least 4 weeks later and dose 3 (final dose) at age12-15 months or 8 weeks after dose 2 (whichever is later).
- y Dose 1 at age 12-14 months: Administer dose 2 (final dose) at least 8 weeks after dose 1.
- y Dose 1 before age 12 months and dose 2 before age 15 months: Administer dose 3 (final dose) at least 8 weeks after dose 2.
- y 2 doses of PedvaxHIB before age 12 months: Administer dose 3 (final dose) at age12-59 months and at least 8 weeks after dose 2.
- y 1 dose administered at age 15 months or older: No further doses needed
- y Unvaccinated at age 15-59 months: Administer 1 dose.
- y Previously unvaccinated children age 60 months or older who are not considered high risk: Catch-up vaccination not required.

For other catch-up guidance, see Table 2. Vaxelis can be used for catch-up vaccination in children younger than age 5 years. Follow the catch-up schedule even if Vaxelis is used for one or more doses. For detailed information on use of Vaxelis see www.cdc.gov/mmwr/volumes/69/wr/mm6905a5.htm.

## Special situations

- y Chemotherapy or radiation treatment: Age 12-59 months
- Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose

Doses administered within 14 days of starting therapy or during therapy should be repeated at least 3 months after therapy completion.

- y Hematopoietic stem cell transplant (HSCT):
- 3-dose series 4 weeks apart starting 6 to 12 months after successful transplant, regardless of Hib vaccination history
- y Anatomic or functional asplenia (including sickle cell disease): Age 12-59 months
- Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose

## Unvaccinated* persons age 5 years or older

- 1 dose
- y Elective splenectomy: Unvaccinated* persons age 15 months or older
- 1 dose (preferably at least 14 days before procedure)
- y HIV infection:

## Age 12-59 months

- Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart
- 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose

## Unvaccinated* persons age 5-18 years

- 1 dose
- y Immunoglobulin deficiency, early component complement deficiency, or early component complement inhibitor use:

## Age 12-59 months

- Unvaccinated or only 1 dose before age 12 months: 2 doses, 8 weeks apart

- 2 or more doses before age 12 months:

1 dose at least 8 weeks after previous dose

* Unvaccinated = Less than routine series (through age 14 months) or no doses (age 15 months or older)

## Hepatitis A vaccination

(minimum age: 12 months for routine vaccination)

## Routine vaccination

- y 2-dose series (minimum interval: 6 months) at age 1223 months

## Catch-up vaccination

- y Unvaccinated persons through age 18 years should complete a 2-dose series (minimum interval: 6 months).
- y Persons who previously received 1 dose at age 12 months or older should receive dose 2 at least 6 months after dose 1.
- y Adolescents age 18 years or older may receive HepA-HepB (Twinrix) as a 3-dose series (0, 1, and 6 months) or 4-dose series (3 doses at 0, 7, and 21-30 days, followed by a booster dose at 12 months).

## International travel

- y Persons traveling to or working in countries with high or intermediate endemic hepatitis A (www.cdc.gov/travel/):
- -Infants age 6-11 months : 1 dose before departure; revaccinate with 2 doses (separated by at least 6 months) between age 12-23 months.
- -Unvaccinated age 12 months or older : Administer dose 1 as soon as travel is considered.

WHITE SPACE INTENTIONALLY LEFT BLANK

<!-- image -->

<!-- image -->

## Hepatitis B vaccination

(minimum age: birth)

## Routine vaccination

- y Mother is HBsAg-negative
- 3-dose series at age 0, 1-2, 6-18 months (use monovalent HepB vaccine for doses administered before age 6 weeks)
-  Birth weight ≥2,000 grams: 1 dose within 24 hours of birth if medically stable
-  Birth weight &lt;2,000 grams: 1 dose at chronological age 1 month or hospital discharge (whichever is earlier and even if weight is still &lt;2,000 grams)
- Infants who did not receive a birth dose should begin the series as soon as possible (see Table 2 for minimum intervals).
- Administration of 4 doses is permitted when a combination vaccine containing HepB is used after the birth dose.
- -Minimum intervals (see Table 2): when 4 doses are administered, substitute 'dose 4' for 'dose 3' in these calculations.
- -Final (3rd or 4th) dose: age 6-18 months (minimum age 24 weeks)
- y Mother is HBsAg-positive
- -Birth dose (monovalent HepB vaccine only): administer HepB vaccine and hepatitis B immune globulin (HBIG) in separate limbs within 12 hours of birth, regardless of birth weight.
- -Birth weight &lt;2000 grams: administer 3 additional doses of HepB vaccine beginning at age 1 month (total of 4 doses).
- -Final (3rd or 4th) dose: administer at age 6 months (minimum age 24 weeks) .
- Test for HBsAg and anti-HBs at age 9-12 months. If HepB series is delayed, test 1-2 months after final dose. Do not test before age 9 months.
- y Mother is HBsAg-unknown

If other evidence suggestive of maternal hepatitis B infection exists (e.g., presence of HBV DNA, HBeAg-positive, or mother known to have chronic hepatitis B infection), manage infant as if mother is HBsAg-positive.

- -Birth dose (monovalent HepB vaccine only):
-  Birth weight ≥2,000 grams: administer HepB vaccine within 12 hours of birth. Determine mother's HBsAg status as soon as possible. If mother is determined to be HBsAgpositive, administer HBIG as soon as possible (in separate limb), but no later than 7 days of age.
-  Birth weight &lt;2,000 grams: administer HepB vaccine and HBIG (in separate limbs) within 12 hours of birth. Administer 3 additional doses of HepB vaccine beginning at age 1 month (total of 4 doses).
- -Final (3rd or 4th) dose: administer at age 6 months (minimum age 24 weeks) .
- If mother is determined to be HBsAg-positive or if status remains unknown, test for HBsAg and anti-HBs at age 9-12 months. If HepB series is delayed, test 1-2 months after final dose. Do not test before age 9 months.

## Catch-up vaccination

- y Unvaccinated persons should complete a 3-dose series at 0, 1-2, 6 months. See Table 2 for minimum intervals.
- y Adolescents age 11-15 years may use an alternative 2-dose schedule with at least 4 months between doses (adult formulation Recombivax HB only).
- y Adolescents age 18 years may receive:
- -Heplisav-B: 2-dose series at least 4 weeks apart
- -PreHevbrio*: 3-dose series at 0, 1, and 6 months
- -HepA-HepB (Twinrix): 3-dose series (0, 1, and 6 months) or 4-dose series (3 doses at 0, 7, and 21-30 days, followed by a booster dose at 12 months).

## Special situations

- y Revaccination is generally not recommended for persons with a normal immune status who were vaccinated as infants, children, adolescents, or adults.
- y Post-vaccination serology testing and revaccination (if anti-HBs &lt;10mlU/mL) is recommended for certain populations, including:
- Infants born to HBsAg-positive mothers
- Persons who are predialysis or on maintenance dialysis
- Other immunocompromised persons
- For detailed revaccination recommendations, see www.cdc. gov/mmwr/volumes/67/rr/rr6701a1.htm.
- *Note: PreHevbrio is not recommended in pregnancy due to lack of safety data in pregnant women.

## Human papillomavirus vaccination

(minimum age: 9 years)

## Routine and catch-up vaccination

- y HPV vaccination routinely recommended at age 11-12 years (can start at age 9 years) and catch-up HPV vaccination recommended for all persons through age 18 years if not adequately vaccinated.
- y 2- or 3-dose series depending on age at initial vaccination: -Age 9-14 years at initial vaccination : 2-dose series at 0, 6-12 months (minimum interval: 5 months; repeat dose if administered too soon)
- -Age 15 years or older at initial vaccination : 3-dose series at 0, 1-2 months, 6 months (minimum intervals: dose 1 to dose 2 = 4 weeks; dose 2 to dose 3 = 12 weeks; dose 1 to dose 3 = 5 months; repeat dose if administered too soon)
- y No additional dose recommended when any HPV vaccine series of any valency has been completed using recommended dosing intervals.

## Special situations

- y Immunocompromising conditions, including HIV infection: 3-dose series, even for those who initiate vaccination at age 9-14 years.
- y History of sexual abuse or assault: Start at age 9 years
- y Pregnancy: Pregnancy testing not needed before vaccination; HPV vaccination not recommended until after pregnancy; no intervention needed if vaccinated while pregnant

WHITE SPACE INTENTIONALLY LEFT BLANK

<!-- image -->

<!-- image -->

## Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2025

## Influenza vaccination

(minimum age: 6 months [IIV3], 2 years [LAIV3],18 years [recombinant influenza vaccine, RIV3])

## Routine vaccination

- y Use any influenza vaccine appropriate for age and health status annually:
- -Age 6 months-8 years who have received fewer than 2 influenza vaccine doses before July 1, 2024, or whose influenza vaccination history is unknown: 2 doses, separated by at least 4 weeks. Administer dose 2 even if the child turns 9 years between receipt of dose 1 and dose 2.
- -Age 6 months-8 years who have received at least 2 influenza vaccine doses before July 1, 2024: 1 dose.
- -Age 9 years or older: 1 dose
- -Age 18 years solid organ transplant recipients receiving immunosuppressive medications: high-dose inactivated (HD-IIV3) and adjuvanted inactivated (aIIV3) influenza vaccines are acceptable options. No preference over other age-appropriate IIV3 or RIV3.
- y For the 2024-25 season, see www.cdc.gov/mmwr/ volumes/73/rr/rr7305a1.htm.
- y For the 2025-26 season, see the 2025-26 ACIP influenza vaccine recommendations.

## Special situations

- y Close contacts (e.g., household contacts) of severely immunosuppressed persons who require a protected environment: should not receive LAIV3. If LAIV3 is given, they should avoid contact with, or caring for such immunosuppressed persons for 7 days after vaccination.

Measles, mumps, and rubella vaccination

(minimum age: 12 months for routine vaccination)

## Routine vaccination

- y 2-dose series at age 12-15 months, age 4-6 years

## Catch-up vaccination

- y Unvaccinated children and adolescents: 2-dose series at least 4 weeks apart*

## Special situations

- y International travel
- -Infants age 6-11 months: 1 dose before departure; revaccinate with 2-dose series at age 12-15 months (12 months for children in high-risk areas) and dose 2 as early as 4 weeks later.*
- -Children age 12 months or older:
-  Unvaccinated: 2-dose series (separated by at least 4 weeks*) before departure
-  Previously received 1 dose: administer dose 2 at least 4 weeks after dose 1*
- y In mumps outbreak settings, for information about additional doses of MMR (including 3rd dose of MMR), see www.cdc. gov/mmwr/volumes/67/wr/mm6701a7.htm
- *Note: MMRV not recommended for ages 12-47 months or ages 13-18 years. Minimum interval between MMRV doses is 3 months.

Note: Persons with an egg allergy can receive any influenza vaccine (egg-based or non-egg based) appropriate for age and health status.

WHITE SPACE INTENTIONALLY LEFT BLANK

Meningococcal serogroup A,C,W,Y vaccination (minimum age: 2 months [MenACWY-CRM, Menveo], 2 years [MenACWY-TT, MenQuadfi]), 10 years [MenACWY-TT/MenB-FHbp, Penbraya])

## Routine vaccination

- y 2-dose series at age 11-12 years; 16 years

## Catch-up vaccination

- y Age 13-15 years: 1 dose now and booster at age 16-18 years (minimum interval: 8 weeks)
- y Age 16-18 years: 1 dose

## Special situations

Anatomic or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use:

- y Menveo*
- Dose 1 at age 2 months: 4-dose series (additional 3 doses at age 4, 6, and 12 months)
- Dose 1 at age 3-6 months: 3- or 4-dose series (dose 2 [and dose 3 if applicable] at least 8 weeks after previous dose until a dose is received at age 7 months or older, followed by an additional dose at least 12 weeks later and after age 12 months)
- Dose 1 at age 7-23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months)
- Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart
- y MenQuadfi
- Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart

Travel to countries with hyperendemic or epidemic meningococcal disease, including countries in the African meningitis belt or during the Hajj (www.cdc.gov/travel/) :

- y Children younger than age 24 months:
- -Menveo* (age 2-23 months)
-  Dose 1 at age 2 months: 4-dose series (additional 3 doses at age 4, 6, and 12 months)
-  Dose 1 at age 3-6 months: 3- or 4-dose series (dose 2 [and dose 3 if applicable] at least 8 weeks after previous dose until a dose is received at age 7 months or older, followed by an additional dose at least 12 weeks later and after age 12 months)
-  Dose 1 at age 7-23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months)

<!-- image -->

## Meningococcal serogroup A,C,W,Y vaccination - continued

- y Children age 2 years or older: 1 dose Menveo* or MenQuadfi

First-year college students who live in residential housing (if not previously vaccinated at age 16 years or older) or military recruits: 1 dose Menveo* or MenQuadfi

Adolescent vaccination of children who received MenACWY prior to age 10 years:

- y Children for whom boosters are recommended because of an ongoing increased risk of meningococcal disease (e.g., those with complement component deficiency, HIV, or asplenia): Follow the booster schedule for persons at increased risk.
- y Children for whom boosters are not recommended (e.g., a healthy child who received a single dose for travel to a country where meningococcal disease is endemic): Administer MenACWY according to the recommended adolescent schedule with dose 1 at age 11-12 years and dose 2 at age 16 years.
* Menveo has two formulations: lyophilized and liquid. The liquid formulation should not be used before age 10 years. See www. cdc.gov/vaccines/vpd/mening/downloads/menveo-single-vialpresentation.pdf.

Note: For MenACWY booster dose recommendations for groups listed under 'Special situations' and in an outbreak setting and additional meningococcal vaccination information, see www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm.

Children age 10 years or older may receive a single dose of Penbraya as an alternative to separate administration of MenACWY and MenB when both vaccines would be given on the same clinic day (see 'Meningococcal serogroup B vaccination' section below for more information).

WHITE SPACE INTENTIONALLY LEFT BLANK

<!-- image -->

## Meningococcal serogroup B vaccination

(minimum age: 10 years [MenB-4C, Bexsero; MenBFHbp, Trumenba; MenACWY-TT/MenB-FHbp, Penbraya])

## Shared clinical decision-making

- y Adolescents not at increased risk age 16-23 years (preferred age 16-18 years)* based on shared clinical decision-making.
- -Bexsero or Trumenba (use same brand for all doses): 2-dose series at least 6 months apart (if dose 2 is administered earlier than 6 months, administer dose 3 at least 4 months after dose 2)

*To optimize rapid protection (e.g., for students starting college in less than 6 months), a 3-dose series (0, 1-2, 6 months) may be administered.

For additional information on shared clinical decision-making for MenB, see www.cdc.gov/vaccines/hcp/admin/downloads/ isd-job-aid-scdm-mening-b-shared-clinical-decision-making.pdf

## Special situations

Anatomic or functional asplenia (including sickle cell disease), persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use.

- -Bexsero or Trumenba (use same brand for all doses including booster doses) 3-dose series at 0, 1-2, 6 months (if dose 2 was administered at least 6 months after dose 1, dose 3 not needed; if dose 3 is administered earlier than 4 months after dose 2, a 4th dose should be administered at least 4 months after dose 3)

For MenB booster dose recommendations for groups listed under 'Special situations' and in an outbreak setting and additional meningococcal vaccination information, see www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm.

Note: MenB vaccines may be administered simultaneously with MenACWY vaccines if indicated, but at a different anatomic site, if feasible.

Children age 10 years or older may receive a dose of Penbraya (MenACWY-TT/MenB-FHbp)  as an alternative to separate administration of MenACWY and MenB when both vaccines would be given on the same clinic day. For age-eligible children not at increased risk, if Penbraya is used for dose 1 MenB, MenB-FHbp (Trumenba) should be administered for dose 2 MenB. For age-eligible children at increased risk of meningococcal disease, Penbraya may be used for additional MenACWY and MenB doses (including booster doses) if both would be given on the same clinic day and at least 6 months have elapsed since most recent Penbraya dose.

## Monkeypox virus vaccination

(minimum age: 18 years [Jynneos])

## Special situations

- y Age 18 years and at risk for monkeypox infection: complete 2-dose series, 28 days apart.

## Risk factors for monkeypox infection include:

- Gay, bisexual, or other MSM, or a person who has sex with gay, bisexual, or other MSM who in the past 6 months have had one of the following:
-  A new diagnosis of at least 1 sexually transmitted disease
-  More than 1 sex partner
-  Sex at a commercial sex venue
-  Sex in association with a large public event in a geographic area where monkeypox virus transmission is occurring
- Persons who are sexual partners of the persons described above
- Persons who anticipate experiencing any of the situations described above
- y Pregnancy: There is currently no ACIP recommendation for Jynneos use in pregnancy due to lack of safety data in pregnant women. Pregnant women with any risk factor described above may receive Jynneos.

For detailed information, see www.cdc.gov/mpox/hcp/vaccineconsiderations/vaccination-overview.html

WHITE SPACE INTENTIONALLY LEFT BLANK

<!-- image -->

<!-- image -->

## Pneumococcal vaccination

(minimum age: 6 weeks [PCV15], [PCV 20]; 2 years [PPSV23])

## Routine vaccination with PCV

- y 4-dose series at 2, 4, 6, 12-15 months

## Catch-up vaccination with PCV

- y Healthy children ages 2-4 years with any incomplete* PCV series: 1 dose PCV
- y For other catch-up guidance, see Table 2.

Note: For children without risk conditions, PCV20 is not indicated if they have received 4 doses of PCV13 or PCV15 or another age appropriate complete PCV series.

## Special situations

Children and adolescents with cerebrospinal fluid leak; chronic heart disease; chronic kidney disease (excluding maintenance dialysis and nephrotic syndrome); chronic liver disease; chronic lung disease (including moderate persistent or severe persistent asthma); cochlear implant; or diabetes mellitus:

## Age 2-5 years

- y Any incomplete* PCV series with:
- 3 PCV doses: 1 dose PCV (at least 8 weeks after the most recent PCV dose)
- Less than 3 PCV doses: 2 doses PCV (at least 8 weeks after the most recent dose and administered at least 8 weeks apart)
- y Completed recommended PCV series but have not received PPSV23.
- Previously received at least 1 dose of PCV20: no further PCV or PPSV23 doses needed
- Not previously received PCV20: administer 1 dose PCV20 or 1 dose PPSV23 administer at least 8 weeks after the most recent PCV dose.

## Age 6-18 years

- y Not previously received any dose of PCV13, PCV15, or PCV20: administer 1 dose of PCV15 or PCV20. If PCV15 is used and no previous receipt of PPSV23, administer 1 dose of PPSV23 at least 8 weeks after the PCV15 dose.**
- y Received PCV before age 6 years but have not received PPSV23
- Previously received at least 1 dose of PCV20: no further PCV or PPSV23 doses needed
- Not previously received PCV20: 1 dose PCV20 or 1 dose PPSV23 administer at least 8 weeks after the most recent PCV dose.
- y Received PCV13 only at or after age 6 years: administer 1 dose PCV20 or 1 dose PPSV23 at least 8 weeks after the most recent PCV13 dose.
- y Received 1 dose PCV13 and 1 dose PPSV23 at or after age 6 years: no further doses of any PCV or PPSV23 indicated.

Children and adolescents on maintenance dialysis, or with immunocompromising conditions such as nephrotic syndrome; congenital or acquired asplenia or splenic dysfunction; congenital or acquired immunodeficiencies; diseases and conditions treated with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and solid organ transplant; HIV infection; or sickle cell disease or other hemoglobinopathies:

## Age 2-5 years

- y Any incomplete* PCV series:
- 3 PCV doses: 1 dose PCV (at least 8 weeks after the most recent PCV dose)
- Less than 3 PCV doses: 2 doses PCV (at least 8 weeks after the most recent dose and administered at least 8 weeks apart)
- y Completed recommended PCV series but have not received PPSV23
- Previously received at least 1 dose of PCV20: no further PCV or PPSV23 doses needed
- Not previously received PCV20: administer 1 dose PCV20 or 1 dose PPSV23 at least 8 weeks after the most recent PCV dose. If PPSV23 is used, administer 1 dose of PCV20 or dose 2 PPSV23 at least 5 years after dose 1 PPSV23.

## Age 6-18 years

- y Not previously received any dose of PCV13, PCV15, or PCV20: administer 1 dose of PCV15 or 1 dose of PCV20. If PCV15 is used and no previous receipt of PPSV23, administer 1 dose of PPSV23 at least 8 weeks after the PCV15 dose.**
- y Received PCV before age 6 years but have not received PPSV23
- Previously received at least 1 dose of PCV20: no additional dose of PCV or PPSV23
- Not previously received PCV20: administer 1 dose PCV20 or 1 dose PPSV23 at least 8 weeks after the most recent PCV dose. If PPSV23 is used, administer either PCV20 or dose 2 PPSV23 at least 5 years after dose 1 PPSV23.
- y Received PCV13 only at or after age 6 years: administer 1 dose PCV20 or 1 dose PPSV23 at least 8 weeks after the most recent PCV13 dose. If PPSV23 is used, administer 1 dose of PCV20 or dose 2 PPSV23 at least 5 years after dose 1 PPSV23.
- y Received 1 dose PCV13 and 1 dose PPSV23 at or after age 6 years: administer 1 dose PCV20 or 1 dose PPSV23 at least 8 weeks after the most recent PCV13 dose and at least 5 years after dose 1 PPSV23.

Pregnancy: no recommendation for PCV or PPSV23 due to limited data. Summary of existing data on pneumococcal vaccination during pregnancy can be found at www.cdc.gov/ mmwr/volumes/72/rr/rr7203a1.htm

For guidance on determining which pneumococcal vaccines a patient needs and when, please refer to the mobile app, which can be downloaded here: wcms-wp.cdc.gov/pneumococcal/ hcp/vaccine-recommendations/app.html

* Incomplete series = Not having received all doses in either the recommended series or an age-appropriate catch-up series. See Table 2 in ACIP pneumococcal recommendations at stacks.cdc.gov/view/cdc/133252
- ** When both PCV15 and PPSV23 are indicated, administer all doses of PCV15 first. PCV15 and PPSV23 should not be administered during the same visit.

<!-- image -->

## Poliovirus vaccination

(minimum age: 6 weeks)

## Routine vaccination

- y 4-dose series at ages 2, 4, 6-18 months, 4-6 years; administer the final dose on or after age 4 years and at least 6 months after the previous dose.
- y 4 or more doses of IPV can be administered before age 4 years when a combination vaccine containing IPV is used. However, a dose is still recommended on or after age 4 years and at least 6 months after the previous dose.

## Catch-up vaccination

- y In the first 6 months of life, use minimum ages and intervals only for travel to a polio-endemic region or during an outbreak.
- y Adolescents age 18 years known or suspected to be unvaccinated or incompletely vaccinated: administer remaining doses (1, 2, or 3 IPV doses) to complete a 3-dose primary series.* Unless there are specific reasons to believe they were not vaccinated, most persons aged 18 years or older born and raised in the United States can assume they were vaccinated against polio as children.

Series containing oral poliovirus vaccine (OPV) , either mixed OPV-IPV or OPV-only series:

- y Total number of doses needed to complete the series is the same as that recommended for the U.S. IPV schedule. See www.cdc.gov/mmwr/volumes/66/wr/mm6601a6.htm?s\_%20 cid=mm6601a6\_w.
- y Only trivalent OPV (tOPV) counts toward the U.S. vaccination requirements.
- Doses of OPV administered before April 1, 2016, should be counted (unless specifically noted as administered during a campaign).
- Doses of OPV administered on or after April 1, 2016, should not be counted.
- For guidance to assess doses documented as 'OPV,' see www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.htm?s\_ cid=mm6606a7\_w.
- y For other catch-up guidance, see Table 2.

## Special situations

- y Adolescents aged 18 years at increased risk of exposure to poliovirus and completed primary series*: may administer one lifetime IPV booster

* Note: Complete primary series consist of at least 3 doses of IPV or trivalent oral poliovirus vaccine (tOPV) in any combination.

For detailed information, see: www.cdc.gov/vaccines/vpd/ polio/hcp/recommendations.html

## Respiratory syncytial virus immunization

(minimum age: birth [Nirsevimab, RSV-mAb, Beyfortus])

## Routine immunization

- y Infants born October - March in most of the continental United States*
- Mother did not receive RSV vaccine or mother's RSV vaccination status is unknown or mother received RSV vaccine in previous pregnancy: administer 1 dose nirsevimab within 1 week of birth-ideally during the birth hospitalization.
- Mother received RSV vaccine less than 14 days prior to delivery: administer 1 dose nirsevimab within 1 week of birth-ideally during the birth hospitalization.
- Mother received RSV vaccine at least 14 days prior to delivery: nirsevimab not needed but can be considered in rare circumstances at the discretion of healthcare providers (see www.cdc.gov/vaccines/vpd/rsv/hcp/child-faqs.html)
- y Infants born April-September in most of the continental United States*
- Mother did not receive RSV vaccine or mother's RSV vaccination status is unknown or mother received RSV vaccine in previous pregnancy: administer 1 dose nirsevimab shortly before start of RSV season.*
- Mother received RSV vaccine less than 14 days prior to delivery: administer 1 dose nirsevimab shortly before start of RSV season.*
- Mother received RSV vaccine at least 14 days prior to delivery: nirsevimab not needed but can be considered in rare circumstances at the discretion of healthcare providers (see www.cdc.gov/vaccines/vpd/rsv/hcp/child-faqs.html)

Infants with prolonged birth hospitalization** (e.g., for prematurity) discharged October through March should be immunized shortly before or promptly after discharge.

## Special situations

- y Ages 8-19 months with chronic lung disease of prematurity requiring medical support (e.g., chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) any time during the 6-month period before the start of the second RSV season; severe immunocompromise; cystic fibrosis with either weight for length &lt;10th percentile or manifestation of severe lung disease (e.g., previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable)**:
- 1 dose nirsevimab shortly before start of second RSV season*
- y Ages 8-19 months who are American Indian or Alaska Native: 1 dose nirsevimab shortly before start of second RSV season*
- y Age-eligible and undergoing cardiac surgery with cardiopulmonary bypass**: 1 additional dose of nirsevimab after surgery. See www.accessdata.fda.gov/drugsatfda\_docs/ label/2023/761328s000lbl.pdf

*Note: While the timing of the onset and duration of RSV season may vary, administration of nirsevimab is recommended October through March in most of the continental United States (optimally October through November or within 1 week of birth). Providers in jurisdictions with RSV seasonality that differs from most of the continental United States (e.g., Alaska, jurisdiction with tropical climate) should follow guidance from public health authorities (e.g., CDC, health departments) or regional medical centers on timing of administration based on local RSV seasonality.

**Note: Nirsevimab can be administered to children who are eligible to receive palivizumab. Children who have received nirsevimab should not receive palivizumab for the same RSV season.

For further guidance, see www.cdc.gov/mmwr/volumes/72/ wr/mm7234a4.htm and www.cdc.gov/vaccines/vpd/rsv/hcp/ child-faqs.html

WHITE SPACE INTENTIONALLY LEFT BLANK

<!-- image -->

## Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2025

## Respiratory syncytial virus vaccination (RSV [Abrysvo])

## Routine vaccination

- y Pregnant at 32 weeks 0 days through 36 weeks and 6 days gestation from September through January in most of the continental United States*: 1 dose Abrysvo. Administer RSV vaccine regardless of previous RSV infection.
- Either maternal RSV vaccination with Abrysvo or infant immunization with nirsevimab (RSV monoclonal antibody) is recommended to prevent severe respiratory syncytial virus disease in infants.
- y All other pregnant women: RSV vaccine not recommended
- y Subsequent pregnancies: additional doses not recommended. No data are available to inform whether additional doses are needed in subsequent pregnancies. Infants born to pregnant women who received RSV vaccine during a previous pregnancy should receive nirsevimab.

*Note: Providers in jurisdictions with RSV seasonality that differs from most of the continental United States (e.g., Alaska, jurisdictions with tropical climate) should follow guidance from public health authorities (e.g., CDC, health departments) or regional medical centers on timing of administration based on local RSV seasonality.

## Rotavirus vaccination (minimum age: 6 weeks)

## Routine vaccination

- y Rotarix: 2-dose series at age 2 and 4 months
- y RotaTeq: 3-dose series at age 2, 4, and 6 months
- y If any dose in the series is either RotaTeq or unknown, default to 3-dose series.

## Catch-up vaccination

- y Do not start the series on or after age 15 weeks, 0 days.
- y The maximum age for the final dose is 8 months, 0 days.
- y For other catch-up guidance, see Table 2.

Tetanus, diphtheria, and pertussis (Tdap) vaccination (minimum age: 11 years for routine vaccination, 7 years for catch-up vaccination)

## Routine vaccination

- y Age 11-12 years: 1 dose Tdap (adolescent booster)
- y Pregnancy: 1 dose Tdap during each pregnancy, preferably in early part of gestational weeks 27-36

Note: Tdap may be administered regardless of the interval since the last tetanus- and diphtheria-toxoid-containing vaccine.

## Catch-up vaccination

- y Age 13-18 years who have not received Tdap: 1 dose Tdap (adolescent booster)
- y Age 7-18 years not fully vaccinated *  with DTaP: 1 dose Tdap as part of the catch-up series (preferably the first dose); if additional doses are needed, use Td or Tdap.
- y Tdap administered at age 7-10 years:
- -Age 7-9 years who receive Tdap should receive the adolescent Tdap booster dose at age 11-12 years
- -Age 10 years who receive Tdap do not need the adolescent Tdap booster dose at age 11-12 years
- y DTaP inadvertently administered on or after age 7 years :
- -Age 7-9 years : DTaP may count as part of catch-up series. Administer adolescent Tdap booster dose at age 11-12 years.
- -Age 10-18 years : Count dose of DTaP as the adolescent Tdap booster dose.
- y For other catch-up guidance, see Table 2.

## Special situations

- y Wound management in persons age 7 years or older with history of 3 or more doses of tetanus-toxoid-containing vaccine: For clean and minor wounds, administer Tdap or Td if more than 10 years since last dose of tetanus-toxoidcontaining vaccine; for all other wounds, administer Tdap or Td if more than 5 years since last dose of tetanus-toxoidcontaining vaccine. Tdap is preferred for persons age 11 years or older who have not previously received Tdap or whose Tdap history is unknown. If a tetanus-toxoid-containing vaccine is indicated for a pregnant adolescent, use Tdap.
- y For detailed information, see www.cdc.gov/mmwr/ volumes/69/wr/mm6903a5.htm.
* Fully vaccinated = 5 valid doses of DTaP or 4 valid doses of DTaP if dose 4 was administered at age 4 years or older

## Varicella vaccination

(minimum age: 12 months)

## Routine vaccination

- y 2-dose series at age 12-15 months, 4-6 years
- Dose 2 may be administered as early as 3 months after dose 1 (a dose inadvertently administered after at least 4 weeks may be counted as valid).

## Catch-up vaccination

- y Ensure persons age 7-18 years without evidence of immunity (see MMWR at www.cdc.gov/mmwr/pdf/rr/rr5604.pdf) have a 2-dose series:
- -Age 7-12 years : Routine interval: 3 months (a dose inadvertently administered after at least 4 weeks may be counted as valid)
- -Age 13 years and older : Routine interval: 4-8 weeks (minimum interval: 4 weeks)

Note: MMRV not recommended for ages 12-47 months or ages 13-18 years (administer MMR and varicella vaccines separately for these age groups). Minimum interval between MMRV doses is 3 months.

WHITE SPACE INTENTIONALLY LEFT BLANK

<!-- image -->

<!-- image -->

## Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2025

## Guide to Contraindications and Precautions to Commonly Used Vaccines

Adapted from Table 4-1 in Advisory Committee on Immunization Practices (ACIP) General Best Practice Guidelines for Immunization: Contraindication and Precautions , Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2024-25 Influenza Season | MMWR (cdc.gov) , and Contraindications and Precautions for COVID-19 Vaccination

| Vaccines and other Immunizing Agents                                      | Contraindicated or Not Recommended 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Precautions 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| COVID-19 mRNAvaccines [Comirnaty, mNexspike, Spikevax]                    | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of an mRNACOVID-19 vaccine 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | • Diagnosed non-severe allergy (e.g., urticaria beyond the injection site) to a component of an mRNACOVID-19 vaccine 3 ; or non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of an mRNACOVID-19 vaccine • Myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine • Multisystem inflammatory syndrome in children (MIS-C) or multisystem inflammatory syndrome in adults (MIS-A) • Moderate or severe acute illness, with or without fever                                      |
| COVID-19 protein subunit vaccine [Nuvaxovid]                              | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of a Nuvaxovid 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | • Diagnosed non-severe allergy (e.g., urticaria beyond the injection site) to a component of Nuvaxovid 3 ; or non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of a Nuvaxovid • Myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine • Multisystem inflammatory syndrome in children (MIS-C) or multisystem inflammatory syndrome in adults (MIS-A) • Moderate or severe acute illness, with or without fever                                                                |
| Influenza, egg-based, inactivated injectable (IIV3)                       | • Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency) • Severe allergic reaction (e.g., anaphylaxis) to any vaccine component 3 (excluding egg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | • Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine • Moderate or severe acute illness with or without fever                                                                                                                                                                                                                                                                                                                                                                                                   |
| Influenza, cell culture-based inactivated injectable (ccIIV3) [Flucelvax] | • Severe allergic reaction (e.g., anaphylaxis) to any ccIIV of any valency, or to any component 3 of ccIIV3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | • Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine • Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IIV, RIV, or LAIV of any valency. If using ccIIV3, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist. • Moderate or severe acute illness with or without fever                                                                      |
| Influenza, recombinant injectable (RIV3) [Flublok]                        | • Severe allergic reaction (e.g., anaphylaxis) to any RIV of any valency, or to any component 3 of RIV3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | • Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine • Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IIV, ccIIV, or LAIV of any valency. If using RIV3, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist. • Moderate or severe acute illness with or without fever                                                                      |
| Influenza, live attenuated (LAIV3) [Flumist]                              | • Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency) • Severe allergic reaction (e.g., anaphylaxis) to any vaccine component 3 (excluding egg) • Children age 2-4 years with a history of asthma or wheezing • Anatomic or functional asplenia • Immunocompromised due to any cause including, but not limited to, medications and HIV infection • Close contacts or caregivers of severely immunosuppressed persons who require a protected environment • Pregnancy • Cochlear implant • Active communication between the cerebrospinal fluid (CSF) and the oropharynx, nasopharynx, nose, ear or any other cranial CSF leak • Children and adolescents receiving aspirin or salicylate-containing medications • Received influenza antiviral medications oseltamivir or zanamivir within the previous 48 hours, peramivir within the previous 5 days, or baloxavir within the previous 17 days | • Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine • Asthma in persons age 5 years old or older • Persons with underlying medical conditions other than those listed under contraindications that might predispose to complications after wild-type influenza virus infection, e.g., chronic pulmonary, cardiovascular (except isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus) • Moderate or severe acute illness with or without fever |

<!-- image -->

## Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2025

| Vaccines and other Immunizing Agents                                        | Contraindicated or Not Recommended 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Precautions 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Dengue(DEN4CYD)                                                             | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3 • Severe immunodeficiency (e.g., hematologic andsolid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infectionwhoareseverelyimmunocompromised) • Lack of laboratory confirmation of a previous dengueinfection                                                                                                                                             | • Pregnancy • HIV infection without evidence of severe immunosuppression • Moderate or severe acute illness with or without fever                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Diphtheria, tetanus, pertussis (DTaP)                                       | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3 • Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7daysofadministrationofpreviousdoseofDTPorDTaP                                                                                                                                                                                                                                           | • Guillain-Barré syndrome(GBS) within 6weeksafter previous dose of tetanus-toxoid-containing vaccine • History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid-containing or tetanus-toxoid-containing vaccine; defer vaccination until at least 10years have elapsed since the last tetanus-toxoid-containing vaccine • For DTaPonly: Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy; defer DTaPuntil neurologic status clarified andstabilized • Moderate or severe acute illness with or without fever          |
| Haemophilusinfluenzae type b(Hib)                                           | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3 • Youngerthanage6weeks                                                                                                                                                                                                                                                                                                                                                                                                             | • Moderate or severe acute illness with or without fever                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| HepatitisA(HepA)                                                            | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3 includingneomycin                                                                                                                                                                                                                                                                                                                                                                                                                  | • Moderate or severe acute illness with or without fever                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Hepatitis B(HepB)                                                           | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3 including yeast • Pregnancy:PreHevbrioisnotrecommendedduetolackofsafetydatainpregnantwomen.UseotherhepatitisBvaccinesif HepBisindicated 4                                                                                                                                                                                                                                                                                          | • Moderate or severe acute illness with or without fever                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Hepatitis A-Hepatitis Bvaccine (HepA-HepB) [Twinrix]                        | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3 includingneomycinand yeast                                                                                                                                                                                                                                                                                                                                                                                                         | • Moderate or severe acute illness with or without fever                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Humanpapillomavirus (HPV)                                                   | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3 • Pregnancy:HPVvaccinationnotrecommended .                                                                                                                                                                                                                                                                                                                                                                                         | • Moderate or severe acute illness with or without fever                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Measles,mumps,rubella(MMR) Measles, mumps,rubella, andvaricella (MMRV)      | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3 • Severe immunodeficiency (e.g., hematologic andsolid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infectionwhoareseverelyimmunocompromised) • Pregnancy • Family history of altered immunocompetence,unless verified clinically or bylaboratory testingasimmunocompetent • For MMRVonly:HIVinfection of any severity andchildren younger than age4years | • Recent (≤11 months) receipt of antibody-containing blood product (specific intervaldependsonproduct) • History of thrombocytopenia or thrombocytopenic purpura • Needfor tuberculin skin testing or interferon-gamma release assay (IGRA) testing • Moderate or severe acute illness with or without fever • For MMRVonly:Personal or family (i.e., sibling or parent) history of seizures of any etiology • IfusingMMRV,seeVaricella/MMRVforadditionalprecautions                                                                                                                                                    |
| MeningococcalACWY(MenACWY) MenACWY-CRM[Menveo] MenACWY-TT[MenQuadfi]        | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3 • For MenACWY-CRMonly:severeallergic reaction to any diphtheriatoxoid-orCRM197-containingvaccine • For MenACWY-TTonly:severe allergic reaction to a tetanus toxoid-containing vaccine                                                                                                                                                                                                                                              | • ForMenACWY-CRMonly:Pretermbirthifyoungerthanage9months • Moderate or severe acute illness with or without fever                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| MeningococcalB(MenB) MenB-4C[Bexsero] MenB-FHbp[Trumenba]                   | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3                                                                                                                                                                                                                                                                                                                                                                                                                                    | • Pregnancy • For MenB-4Conly: Latex sensitivity • Moderate or severe acute illness with or without fever                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| MeningococcalABCWY (MenACWY-TT/MenB-FHbp)[Penbraya]                         | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3 • Severe allergic reaction to a tetanus toxoid-containing vaccine                                                                                                                                                                                                                                                                                                                                                                  | • Moderateorsevereacuteillness,withorwithoutfever                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Mpox[Jynneos]                                                               | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3                                                                                                                                                                                                                                                                                                                                                                                                                                    | • Moderate or severe acute illness, with or without fever                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Pneumococcal conjugate (PCV)                                                | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3 • Severe allergic reaction (e.g., anaphylaxis) to any diphtheria-toxoid-containing vaccine or itscomponent 3                                                                                                                                                                                                                                                                                                                       | • Moderate or severe acute illness with or without fever                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Pneumococcalpolysaccharide (PPSV23)                                         | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3                                                                                                                                                                                                                                                                                                                                                                                                                                    | • Moderate or severe acute illness with or without fever                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Poliovirus vaccine, inactivated (IPV)                                       | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3                                                                                                                                                                                                                                                                                                                                                                                                                                    | • Pregnancy • Moderate or severe acute illness with or without fever                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| RSVmonoclonalantibody (RSV-mAb)                                             | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 5                                                                                                                                                                                                                                                                                                                                                                                                                                    | • Moderate or severe acute illness with or without fever                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Respiratory syncytial virus vaccine (RSV)                                   | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3                                                                                                                                                                                                                                                                                                                                                                                                                                    | • Moderate or severe acute illness with or without fever                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Rotavirus (RV) RV1[Rotarix] RV5[RotaTeq]                                    | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3 • Severe combinedimmunodeficiency (SCID) • History of intussusception                                                                                                                                                                                                                                                                                                                                                              | • AlteredimmunocompetenceotherthanSCID • Chronic gastrointestinal disease • RV1only: Spina bifida or bladder exstrophy • Moderate or severe acute illness with or without fever                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Tetanus, diphtheria, andacellular pertussis (Tdap) Tetanus, diphtheria (Td) | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3 • ForTdap only: Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7daysofadministration of previous dose of DTP, DTaP, orTdap                                                                                                                                                                                                                | • Guillain-Barré syndrome(GBS) within 6weeksafter a previous dose of tetanus-toxoid-containing vaccine • History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid-containing or tetanus-toxoid-containing vaccine; defer vaccination until at least 10years have elapsed since the last tetanus-toxoid-containing vaccine • ForTdap only: Progressive or unstable neurological disorder, uncontrolled seizures, or progressive encephalopathy until a treatment regimen has beenestablished andthecondition has stabilized • Moderate or severe acute illness with or without fever |
| Varicella (VAR) Measles, mumps,rubella, andvaricella (MMRV)                 | • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccinecomponent 3 • Severe immunodeficiency (e.g., hematologic andsolid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infectionwhoareseverelyimmunocompromised) • Pregnancy • Family history of altered immunocompetence,unless verified clinically or bylaboratory testingasimmunocompetent • For MMRVonly:HIVinfection of any severity andchildren younger than age4years | • Recent (≤11 months) receipt of antibody-containing blood product (specific intervaldependsonproduct) • Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24hoursbefore vaccination (avoid use of these antiviral drugs for 14daysafter vaccination) • Useofaspirin or aspirin-containing products • Moderate or severe acute illness with or without fever • IfusingMMRV,seeMMR/MMRVforadditionalprecautions                                                                                                                                                                              |

<!-- image -->

## Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2025

In addition to the recommendations presented in the previous sections of this immunization schedule, ACIP has approved the following recommendations by majority vote since October 24, 2024.

| Vaccines                                                                                                                                                                                                                                                                                                        | Recommendations                                                                                                                                                                                                                                                                                                                                                                                                                     | Effective Date of Recommendation*                                                                                                                                                                                                                                                                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Meningococcal (MenACWYCRM/ MenB-4C, Penmenvy)                                                                                                                                                                                                                                                                   | MenABCWY vaccine may be used when both MenACWY and MenB are indicated at the same visit in: 1. healthy persons aged 16-23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine and 2. persons aged ≥10 years who are at increased risk for meningococcal disease (e.g., because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia) | June 25, 2025                                                                                                                                                                                                                                                                                                   |
| Influenza                                                                                                                                                                                                                                                                                                       | ACIP reaffirms the recommendations for routine annual influenza vaccination of all persons aged ≥ 6 months who do not have contraindications for the 2025-2026 season                                                                                                                                                                                                                                                               | July 22, 2025                                                                                                                                                                                                                                                                                                   |
| Influenza                                                                                                                                                                                                                                                                                                       | ACIP recommends only single-dose formulations of annual influenza vaccines that are free of thimerosal as a preservative for three populations: - Children 18 years or younger - Pregnant women - All adults                                                                                                                                                                                                                        | July 22, 2025                                                                                                                                                                                                                                                                                                   |
| RSV monoclonal antibody (Clesrovimab)                                                                                                                                                                                                                                                                           | ACIP recommends infants aged < 8 months born during or entering their first RSV season who are not protected by maternal vaccination receive one dose of clesrovimab.                                                                                                                                                                                                                                                               | August 4, 2025                                                                                                                                                                                                                                                                                                  |
| Note: As of May 29, 2025, the schedule incorporates the HHS directive regarding COVID-19 vaccine recommendations. (Changes were made to tables and notes for COVID-19 vaccines in pregnant women and children/adolescents ages 6 months through 17 years who are not moderately or severely immunocompromised). | Note: As of May 29, 2025, the schedule incorporates the HHS directive regarding COVID-19 vaccine recommendations. (Changes were made to tables and notes for COVID-19 vaccines in pregnant women and children/adolescents ages 6 months through 17 years who are not moderately or severely immunocompromised).                                                                                                                     | Note: As of May 29, 2025, the schedule incorporates the HHS directive regarding COVID-19 vaccine recommendations. (Changes were made to tables and notes for COVID-19 vaccines in pregnant women and children/adolescents ages 6 months through 17 years who are not moderately or severely immunocompromised). |